Barcelona, 3 March 2011. A clinical research trial led by Dr. Javier Cortés, the head of the BREAST CANCER Programme of the Vall d’Hebron Hospital and the VHIO, has demonstrated that eribulin (a chemotherapy drug based on Halichondria okadai, a sea sponge of animal origin) improves the prognosis of patients suffering from metastatic breast cancer. The trial, A Phase III open-label randomised study (EMBRACE) of eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer, is being published today in The Lancet, and its objective was to demonstrate the efficacy of this treatment.
Related Posts
Sponsored Walking for Breast Cancer Research at VHIO: El Paseíco de la Mama once again surpasses all expectations
Inés Gasén was diagnosed with breast cancer during her pregnancy – not only naturally provoking fear and uncertainty for her…
10 Jul 2014
Cancer Core Europe proudly announces the appointment of Professor Fabien Calvo as Chief Scientific officer
Source: Gustave Roussy Cancer Campus Grand Paris An appointment reflecting the ambitions of Cancer Core Europe As of December…
16 Dec 2014
Coming to VHIO 07-09 November: 2013 International Symposium on Progress Towards Individualized Cancer Treatments
Progress Towards Individualized Cancer Treatments 07 – 09 November 2013, marks the 17th International Symposium in the annual series of…
10 Sep 2013
VHIO to host Nano World Cancer Day 2017 at national level
On February 2nd 2017 as we gear up to World Cancer Day to be celebrated globally on February 04, VHIO…
26 Jan 2017
VHIO brings breaking data to Stockholm: the 2011 European Multidisciplinary Cancer Congress
Aflibercept vs placebo and FOLFIRI for MCRC
06 Oct 2011
Josep Tabernero´s candidacy for presidency of the European Society for Medical Oncology and an invitation to ESMO Members to cast their votes before Monday 15 June 2015
VHIO is delighted to announce the candidacy of Josep Tabernero, our Director, for presidency of the European Society for Medical…
01 Jun 2015
WIN 2016 Symposium June 27-28, Paris: Innovative Approaches to Improve Cancer Patient Outcomes
WIN will address the most critical question facing clinical cancer research: Why the improvement of survival still remains limited for…
21 Dec 2015
Studies Report New Findings on Treatment Options for Mesothelioma
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target Is PD-L1 a…
30 Sep 2014
VHIO spin-off Peptomyc S.L. secures 4.2 million euros in Series A led by Alta Life Sciences
Source: Alta Life Sciences Peptomyc S.L, a Barcelona-based biotech company developing new peptide therapeutics for the treatment of cancer patients,…
08 Sep 2017
Three drugs may be better than one for certain patients with advanced colorectal cancer
Source: EORTC-NCI-AACR Symposium Barcelona, 20 November 2014 – Patients with a form of advanced colorectal cancer that is driven by a…
20 Nov 2014
A third consecutive year closes with VHIR recognition of upcoming VHIO talent
For the third year in a row VHIO´s Mouse Models of Cancer Therapies Group, led by Laura Soucek, has been awarded…
30 Dec 2015
ASCO Annual Meeting 2012: Largest study on women with breast cancer treated with PI3K inhibitors
ASCO Annual Meeting 2012: Largest study on women with breast cancer treated with PI3K inhibitors.
– The study was presented at the annual meeting of ASCO (American Society of Clinical Oncology) revealing findings surrounding the largest sample of breast cancer patients treated with this group of drugs.
– This research presented at ASCO was honored through a Merit Award from the Conquer Cancer Foundation — testament to its high quality and important scientific interest.
06 Jun 2012
VHIO´s Enriqueta Felip receives Merck´s Grant for Oncology Innovation for novel blood-based approach towards more precisely guiding treatment with immunotherapy
Officially announced during this month´s annual Congress of the European Society of Medical Oncology (ESMO), 07 – 11 October in…
18 Oct 2016
VHIO spinout Mosaic Biomedicals: accelerating clinical trials of first-in-class therapeutic antibody for cancer
Mosaic Biomedicals SL today announced a merger with Northern Biologics Inc. that will enable the accelerated development of MSC-1, a…
19 Dec 2016
VHIO participation at AACR´s Annual Meeting 2014
Barcelona, April 11, 2014. Preclinical, translational and clinical researchers and physician-scientists from the Vall d’Hebron Institute of Oncology (VHIO) attended…
14 Apr 2014
